Table 2. Symptoms Reported During the Acute Phase of SARS-CoV-2 Infection and 2 or More Months Later (Persistent Symptoms).

Symptom	No./total No. (%) [95% CI]
	Symptoms experienced during the acute phase (n = 3972)	Persistent symptoms (≥2 mo) among participants with symptoms at acute phase (n = 2647)
≥1 Symptom	2647/3972 (66.6) [65.1-68.1]	861/2647 (32.5) [30.7-34.3]
Cough	1091/3972 (27.5) [26.1-28.9]	81/1091 (7.4) [6.0-9.2]
Dyspnea	614/3972 (15.5) [14.4-16.6]	163/614 (26.5) [23.1-30.3]
Thoracic pain	367/3972 (9.2) [8.4-10.2]	49/367 (13.4) [10.1-17.4]
Palpitation	173/3972 (4.4) [3.8-5.0]	46/173 (26.6) [20.3-33.9]
Articular pain	413/3972 (10.4) [9.5-11.4]	111/413 (26.9) [22.7-31.5]
Myalgia	1333/3972 (33.6) [32.1-35.1]	98/1333 (7.4) [6.0-8.9]
Headache	1456/3972 (36.7) [35.2-38.2]	89/1456 (6.1) [5.0-7.5]
Cranial nerve abnormalities	7/3972 (0.2) [0.1-0.4]	2/7 (28.6) [5.1-69.7]
Sensory impairment	121/3972 (3.0) [2.5-3.6]	28/121 (23.1) [16.2-31.9]
Speech impairment	31/3972 (0.8) [0.5-1.1]	4/21 (19.0) [6.3-42.6]
Hearing impairment	58/3972 (1.5) [1.1-1.9]	12/58 (20.7) [11.6-33.7]
Anosmia or ageusia	978/3972 (24.6) [23.2-26.0]	264/978 (27.0) [24.3-29.9]
Fever	1581/3972 (39.8) [38.2-41.3]	8/1581 (0.5) [0.2-1.0]
Asthenia	1832/3972 (46.1) [44.6-47.7]	378/1832 (20.6) [18.8-22.6]
Attention or concentration disorders	376/3972 (9.5) [8.6-10.4]	84/376 (22.3) [18.3-27.0]
Memory loss	172/3972 (4.3) [3.7-5.0]	70/175 (40.0) [32.8-47.7]
Sleep disorders	421/3972 (10.6) [9.7-11.6]	154/421 (36.6) [32.0-41.4]
Cutaneous disorders	97/3972 (2.4) [2.0-3.0]	21/97 (21.6) [14.2-31.4]
Nausea	322/3972 (8.1) [7.0-9.0]	24/322 (7.5) [4.9-11.0]
Diarrhea	419/3972 (10.5) [9.6-11.6]	20/419 (4.8) [3.0-7.4]